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Cardiovascular disease (CVD) accounts for approxi-
mately 50% of all deaths in Europe and, as the primary
cause of disease burden, is estimated to cost the European
economy Euros 196 billion, annually [1]. Major modifiable
risk factors for CVDs include tobacco use, dyslipidaemia,
hypertension, Type 2 diabetes mellitus (T2D), poor diet,
physical inactivity and obesity [2e4]. Because these risk
factors tend to co-exist with a multiplicative, rather than
additive, effect on CV risk [5e7], it is important to assess
and treat the individual patient’s overall CV risk [2,3].
Moreover, since T2D and CVD have some overlapping risk
factors and often co-exist, the 2013 European Society of
Cardiology (ESC)/European Association for the Study of
Diabetes (EASD) Guidelines on Diabetes, Pre-diabetes, and
Cardiovascular Diseases suggest that all patients with CVD
or CV risk factors should routinely be screened for T2D [8]
using either glycated haemoglobin (HbA1c) or fasting
plasma glucose (FPG) as markers. Diabetes risk scores
should be used in advance of deciding which patients
would benefit from glycaemia testing.
Current best practice for reducing CV risk includes life-
style changes such as improved diet, weight loss, regular
physical activity, and (when applicable) smoking cessation,together with pharmacotherapy to improve lipid profile and
blood pressure [2,8e11,18]. Although the management of
CV risk factors has improved over recent years [12], the
clinical impact of these gains will potentially be attenuated
by the increasing pandemics of obesity and T2D as athero-
sclerotic disease is accelerated in T2D [12e14]. Currently,
the worldwide incidence of T2D is predicted to increase
from 342 million in 2011 to 534 million by 2030 [15] and the
number of CV deaths is predicted to increase from 17.1
million in 2004 to 23.6 million in 2030 [16]. The fact that
both CVD and T2D are strongly related to a western lifestyle
(i.e. smoking, insufficient exercise, and a high-fat, high-
refined sugar diet comprising a large proportion of processed
food) suggests that greater efforts are needed at every level
(including Governmental policies targeted at the food
industry) to encourage lifestyle changes. A tool kit providing
practical advice for healthcare professionals has recently
been developed to aid this process [8,17].
2. Statins are safe and effective for the reduction of CV
risk in a wide range of patients
Dyslipidaemia e characterised by increased concentra-
tions of the pro-atherogenic apolipoprotein-B containing
lipoproteins (low-density lipoproteins [LDLs], very-low
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VLDL-/CM-remnants) and reduced levels of potentially
antiatherogenic apolipoprotein-A-I containing high-density
lipoproteins [HDLs] e accounts for a significant propor-
tion of the population-attributable risk for cardiovascular
disease [7]. Numerous clinical trials have demonstrated the
benefits of lowering LDL-C with statins for the reduction of
CV risk in a wide range of populations [10,19e24]. For
example, the Cholesterol Treatment Trialist’s Collaboration
(CTTC) meta-analyses showed that each 1 mmol/L
(38.6 mg/dL) reduction in LDL-C is associated with
a significant 21% proportional reduction in major vascular
events in people with (0.79, 0.72e0.86; P < 0.0001) and
without T2D (0.79, 0.76e0.82; P < 0.0001) [21]. More
recent studies have demonstrated that statins are similarly
beneficial for the primary and secondary prevention of CVD
[10,20,24] and that the relative risk reduction is similar even
in patients with very low absolute CV risk [22]. These
results are partially explained by intra-vascular ultrasound
(IVUS) studies showing that intensive LDL-C lowering
using statins can significantly slow, and even reverse, the
progression of atherosclerotic plaques in people with coro-
nary heart disease (CHD) [25,26]. Consequently, statins
remain the first-line lipid-lowering strategy for the vast
majority of people with CV risk, including those with T2D.
Statins are associated with an excellent safety and
tolerability profile [22,27e32]. Although observational
studies had raised concerns about a possible link between
long-term statin use and the increased incidence of non-CV
morbidity or mortality (e.g. cancer, memory loss and
psychiatric disorders), such claims have been fully refuted
by randomised, placebo-controlled clinical trials
[22,30e32]. However, no drugs are completely risk-free
and a number of dose-dependent adverse events (AEs)
have been reported for statins, the most common of which
include elevations in liver enzymes, myalgia, and (rarely)
rhabdomyolysis [27e29,33]. Reassuringly, a meta-analysis
of 72 trials involving 159,458 patients showed no signifi-
cant difference between statins and placebo on the inci-
dence of rhabdomyolysis (0.25% versus 0.25%; OR 1.05,
95% CI 0.84e1.31) or elevated creatine kinase level (OR
1.09, 95% CI 0.85e1.41) [27]. However, of the currently
used statins, the 80 mg dose of simvastatin was signifi-
cantly associated with an increased incidence of myopathy
in both the AggrastateZocor (AeZ) study and the Study of
the Effectiveness of Additional Reductions in Cholesterol
and Homocysteine (SEARCH) study [34]. However, statin-
related AEs are usually resolved by drug discontinuation
and/or by reducing the statin dose and, in general, the
benefits of statin use far outweigh the possible risks, even in
primary prevention patients with very low CV risk [22,24].
A number of studies have raised the possibility that statins
are associated with an increased relative risk of developing
T2D [35,36,38e48], although the absolute risk remains small
and may vary by baseline risk of developing T2D. This is
a potential concern because long-term T2D is associatedwith, on average, a 2-fold increased risk of CVmorbidity and
mortality [49e51] and an increased incidence of death from
non-CV related disorders, including several cancers, infec-
tious diseases, external causes, intentional self-harm, and
degenerative disorders [51]. Of course, risk levels vary
depending on the duration of T2D and the presence of co-
morbidities, such as chronic kidney disease. Nevertheless,
approximately 10% of all CV deaths in the developed world
over the past 10 years were attributed to T2D [50]. In 2012,
the US Food and Drug Administration (FDA) changed their
labelling requirements for statins to include a warning about
the possibility of increased blood sugar and HbA1c levels
[52]. This sparked an ongoing debate about the risks and
implications of developing T2D with statin use that led the
American Heart Association (AHA)/American College of
Cardiology (ACC) to incorporate new advice in their 2013
cholesterol treatment guidelines [11]. The aim of this paper is
to examine the evidence leading to these concerns and to
provide practical guidance for primary care physicians on the
use of statins in people with, or at risk of developing, T2D.
3. Guidelines for the management of dyslipidaemia and
CVD
International guidelines for the management of dyslipi-
daemia and CVD recommend reducing LDL-C to specific
targets or by specific statin regimes depending on
a patient’s overall level of CV risk [2e4,8,11,53e55].
Patients with established T2D are either classified as high
risk or, for those with T2D and at least one other CV risk
factor or target organ damage, very high risk. For patients
without T2D, CV risk stratification is carried out using the
European Systematic Coronary Risk Evaluation (SCORE)
charts in Europe, the New Pooled Cohort Risk Equation
(ASCVD) in the USA and Framingham Risk Score (FRS)
charts in Canada [2,3,11,53e55], although some countries
(e.g. UK) suggest statins for all patients with type 2 dia-
betes above certain age. The identification of low HDL-C
levels as a residual risk factor for CVD [56] has led to
the integration of HDL-C values into recent charts [2,3,8,9].
This is particularly important for people with obesity,
a sedentary lifestyle, pre-diabetes or undiagnosed T2D,
who typically have low levels of HDL-C in addition to
elevated levels of triglyceride and remnant particles.
Most guidelines suggest lowering LDL-C to 2.5 mmol/
L (100 mg/dL) in patients with high CV risk (T2D or
SCORE 5e9% or marked elevations in single risk factors or
FRS 10e19%) and to 1.8 mmol/L (70e80 mg/dL) or
a50% reduction in LDL-C in those with very high CV risk
(T2D and other CV risk factors or SCORE  10% or
ASCVD 7.5% or FRS 20% (whichmay be revised down
shortly to 10%) or established CVD) [2e4,8,9,11,15]. The
recommended first-line treatment for the majority of patients
with raised LDL-C is lifestyle modification to include
a Mediterranean-type diet, regular exercise, smoking
cessation, and weight loss [2e4,8,9,11,15,17,53,55,57]. In
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high risk patients that fail to achieve their recommended
LDL-C target using non-pharmacological interventions
[2e4,8,9,11,15,53,55,57] and, according to the 2013 ESC/
EASD Guidelines for Diabetes, Pre-diabetes and CVDs, for
all patients with T2D and high CV risk, irrespective of their
baseline LDL-C level [8]. Although the recent guidelines
from the AHA/ACC recommended high- and moderate-
intensity statin therapy rather than LDL-C targets, patients
with T2D and either CVD or other risk factors were among
those targeted for intensive LDL-C lowering [11].
4. Guidelines for the diagnosis, prevention and
treatment of T2D4.1. T2D diagnosisThe development of T2D is a gradual process that is
typically associated with a cluster of modifiable risk factors,
including atherogenic dyslipidaemia, raised blood pressure,
obesity, smoking and/or a sedentary lifestyle, all of which
increase the risk of CVD. Thus among those with impaired
glucose tolerance (IGT) and/or impaired fasting glucose
(IFG) (pre-diabetes), the risk of incident CVD may be
elevated due to the presence of the associated risk factors.
Some, but not all, patients with pre-diabetes go on to develop
T2D. Although T2D typically occurs after middle age, the
increasing incidence of childhood obesity has resulted in
a trend towards a younger age of onset. Other non-modifiable
risk factors for T2D include a family history of T2D, male
gender, and Asian or other non-white ethnicity [8].
Recommendations for the diagnosis of T2D have become
more consistent in recent years and now include HbA1c
levels 6.5% (48 mmol/L) or FPG  7.0 mmol/L (126 mg/
dL) or 2-h oral glucose tolerance testing (OGTT)
11.1 mmol/L (200 mg/dL) [4,8,15,58,59]. HbA1c testing
should be performed in a laboratory, using a method that is
National Glycohaemoglobin Standardization Program-
(NGSP-) [60] certified and standardised to the Diabetes
Complications and Control Trial (DCCT) assay. All guide-
lines recommend similar thresholds for the diagnosis of IGT
(FPG< 7.0mmol/L [126mg/dL] and/or 2-hOGGT 7.8 but
<11 mmol/L [200 mg/dL]) and the recommended threshold
for IFG according to WHO is 6.1 mmol/L (110 mg/dL).4.2. T2D risk stratificationIn 2011, approximately 342 million people worldwide
(60 million people in Europe) had T2D and another 300
million had the characteristics of pre-diabetes (e.g. insulin
resistance, hyperinsulinaemia, IGT or IFG) [15]. Increas-
ingly, evidence suggests that dysglycaemia per se is
a modest causal factor for CVD; that said approximately
60% of patients with T2D will develop CVD. A major
problem in the treatment of patients with pre-diabetes or
T2D is that patients may not display symptoms for manyyears, by which time secondary complications such as
coronary, cerebrovascular and microvascular disease, can be
well-established. Given that the level of CV risk increases
with the duration of T2D [61,62], early and effective
modification of CVD risk, whilst mitigating the risk of
developing/worsening T2D, would seem sensible. Indeed,
the benefits of earlier T2D screening are demonstrated by
a recent analysis of data from 51,526 people with newly
diagnosed T2D in Scotland, in which the majority of patients
were screened for T2D within an acceptable period and the
prevalence of retinopathy at first screening was significantly
lower than that observed in previous studies [63].
To improve the early detection and management of
people with or at risk of developing T2D, the 2013 ESC/
EASD guidelines recommend a combined approach for CV
and T2D risk screening [8]. All patients with CVD should
undergo HbA1c and/or FPG testing. For the general pop-
ulation and in those with associated abnormalities (obesity,
hypercholesterolaemia, family history of T2D etc.), a two-
step approach is recommended that requires risk stratifi-
cation using score charts followed by biochemical assess-
ment only in those patients with high T2D risk. Several
score charts are available for predicting the 10-year risk of
developing T2D based on age, gender, ethnicity, family
history of T2D and BMI. Of these, the FINnish Diabetes
RIsk Score (FINDRISC [64]; Fig. 1) is commonly used in
Europe, but others are equally effective [65,66].4.3. Prevention and treatment of T2D and CVD in
people with high T2D riskIn people with a high risk of developing T2D (including
those with established IGT and/or HbA1c levels in the
range 6.0e6.4%), conversion to T2D can be delayed and, in
some cases, prevented by timely intervention with intensive
lifestyle changes and/or T2D medications [8,67e73]. Of
these strategies, the Diabetes Prevention Program (DPP)
(N ¼ 3234) showed that 2.8 year’s (median) treatment with
lifestyle change was more effective for the reduction of
incident T2D among IGT individuals than treatment with
metformin (58% and 31% versus placebo, respectively)
[68]. A 10-year follow-up of the DPP study (N ¼ 2766), in
which each patient group was assigned intensive lifestyle
changes in addition to their original treatment, showed that,
although the incidences of T2D during this extended
follow-up period were similar in all 3 groups (5.9; 95% CI
5.1e6.8 per 100 person-years with lifestyle, 4.9 [4.2e5.7]
with metformin and 5.6 [4.8e6.5] with placebo), the
cumulative incidence of T2D remained lowest in the life-
style group (34% with lifestyle versus placebo and 18%
for metformin versus placebo) [67]. The equalisation of
incidences during the DPP study was most likely due to the
lifestyle change intervention offered to all three groups. A
number of other studies have demonstrated similar obser-
vations [70e72], leading guidelines to recommend inten-
sive lifestyle changes as the first-line treatment for the
Fig. 1. FINnish Diabetes Risk Score (FINDRISC) to assess the 10-year risk of developing T2D in adults. Adapted from Ryden et al [8].
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lowed by metformin if necessary [8].
According to international guidelines, CV risk reduction
in people with established T2D should include a combina-
tion of intensive lifestyle changes, glycaemic control (tar-
geting HbA1c <7.0%), BP reduction [<140/85 mmHg],
and lipid management as previously described in Section 2
[4,8,15,58,59,74]. However, a meta-analysis of five
prospective randomised controlled trials (N ¼ 33,040)
showed that, although intensive glycaemic control was
associated with significant reductions in HbA1c, non-fatal
MI and CHD risk, the reduction in CV events (2.9 per
200 T2D patients treated over 5 years) was far more modest
than that achieved either with lipid-lowering therapy (8.2
fewer events for each mmol/L reduction LDL-C) or anti-
hypertensive treatment (12.5 fewer events per 4 mmHg
reduction in systolic blood pressure) [75]. In people withoutT2D but with high T2D risk, The Diabetes REduction
Assessment with ramipril and rosiglitazone Medication
(DREAM) study (N ¼ 5269) showed that treatment with
rosiglitazone increased the likelihood of reversion to nor-
moglycaemia and reduced the incidence of T2D but had
little effect on CV event rates [69]. More recently, the 18-
month Carotid Atherosclerosis: Metformin For Insulin
Resistance (CAMERA) trial demonstrated a significant
reduction in glycaemia when metformin was added to
a statin in non-diabetic subjects with established CVD and
large waist circumference (N ¼ 173) but no change in
carotid intima-media thickness (CIMT) [76]. Although the
Actos Now for Prevention of Diabetes (ACT NOW) trial
showed a slower rate of CIMT progression in people with
prediabetes treated with pioglitazone versus placebo, this
result was independent of changes in glycaemia [77].
Overall, results suggest that the CV risk associated with
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with effective management of dyslipidaemia and blood
pressure should be a priority for CV risk reduction in
people with, or at risk of developing, T2D.5. Evidence for the diabetogenicity of statins
The first study to report on T2D risk with statin usewas the
all-male West Of Scotland Coronary Prevention Study
(WOSCOPS; N ¼ 5974) [37]. This study suggested that,
compared to placebo, pravastatin was associated with a 30%
relative risk reduction (P¼ 0.042) in the hazard of developing
T2D after 5 years. Therefore, the finding in Justification for
the Use of Statins in Primary Prevention: An Intervention
Trial Evaluating Rosuvastatin (JUPITER) study (N¼ 17,802)
that treatment with rosuvastatin 20 mg/day for 1.9 years was
associated with a significant 25% relative risk increase in
T2D among middle-aged men and women with ‘normal’
levels of LDL-C (median 108 mg/dL) and high levels of C-
reactive protein (CRP) (median 4.2 mg/L), (3.0% vs. 2.4%)
versus placebo (P¼ 0.01), was surprising [36]. This increase
was accompanied by a small but significant increase in
HbA1c levels. Overall, these findings led to a reappraisal of
the original notion that statins may lessen T2D risks.
To investigate the totality of evidence provided by all
trials with relevant data, Sattar et al. carried out a meta-
analysis of 13 statin trials including 91,140 patients
without T2D, which involved retrieving data for several of
the existing trials [39]. Overall, standard-dose statin therapy
(atorvastatin 10 mg, pravastatin 40 mg, simvastatin 40 mg or
rosuvastatin 20 mg) was associated with a 9% increased risk
for T2D over 4 years (OR 1.09; 95% CI 1.02e1.17), with
little heterogeneity (I2 ¼ 11%) between trials (Fig. 2). Later,
a post-hoc analysis of the Stroke Prevention by Aggressive
Reduction in Cholesterol Levels (SPARCL) trial (N ¼ 3803)
showed that new-onset T2D developed in 166 of 1905
patients randomised to atorvastatin 80 mg/day and in 115 of
1898 patients in the placebo group (8.71% vs. 6.06%,
adjusted HR: 1.37; 95% CI: 1.08e1.75; P ¼ 0.011) [41].
The implications of these results are discussed in Section 7.Fig. 2. Statins are associated with an increased ri5.1. The degree of statin diabetogenicity increases
with statin doseTo further investigate and substantiate the potential
effect of statins on T2D risk, Preiss et al. carried out a meta-
analysis of data from five trials in which 32,752 participants
without T2D at baseline were randomised to receive
intensive- versus standard-dose statins [38]. The study
demonstrated a higher risk of developing T2D (OR, 1.12) in
recipients of intensive-dose statins, with no apparent
heterogeneity between trials (I2 ¼ 0%) (Fig. 3). Together,
these results suggest that the diabetogenic effects of statins
are likely to be dose-related.5.2. People with pre-existing risk factors for T2D are
more likely to develop statin-mediated T2D than
those withoutA recent post-hoc analysis of data from the Treating to
New Targets (TNT) (N ¼ 7595) and IDEAL (N ¼ 7461)
trials showed that the statin-mediated development of T2D
is associated with raised FPG levels (>100 mg/dL) and by
the presence of components of the metabolic syndrome,
including elevated levels of fasting TGs (>150 mg/dl), BMI
>30 kg/m2, and hypertension [41,78]. Among patients with
0e1 T2D risk factors at baseline, the risk of developing
T2D during a median 5 years follow up was similar among
patients treated with high-dose statins (atorvastatin 80 mg or
simvastatin 40 mg) and moderate-dose statins (atorvastatin
10 mg or simvastatin 20 mg) (3.22% vs. 3.35%, respec-
tively; HR: 0.97; 95% CI: 0.77e1.22). Among patients with
2e4 risk factors, T2D developed in 14.3% of the high-dose
group and in 11.9% of the lower-dose groups (HR: 1.24;
95% CI: 1.08e1.42; P ¼ 0.0027). This suggests that the
dose-related diabetogenic effects of statins might be most
apparent for people with pre-existing risk factors for T2D,
but further research is needed to confirm this possibility.
Similarly, a recent analysis of the JUPITER study
showed that, compared to placebo, rosuvastatin-treated
subjects with 1 risk factor for T2D (metabolicsk of T2D. Adapted from Sattar et al. [39].
Fig. 3. The diabetogenic effects of statins appear to be dose-related. Adapted from Preiss et al [38].
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HbA1c > 6%) had a 28% increased risk of developing T2D
(HR 1.28, 95% CI 1.07e1.54, P ¼ 0.01), whereas the risk
in patients without any risk factors was negligible [35,79].
In this study, there was a significant 39% (95% CI
0.47e0.79 P < 0.0001) reduction in the primary endpoint
(MI, stroke, admission to hospital for unstable angina,
arterial revascularisation, or CV death) in rosuvastatin-
treated patients with risk factors for T2D and a 52% (CI
0.33e0.68 P ¼ 0.0001) reduction in patients without.
Overall, 134 total vascular events or deaths were avoided
for every 54 new cases of T2D in the high-risk group,
compared to 86 total vascular events or deaths with no
excess of incident T2D in the low-risk group. Even in
people who developed T2D (270 on rosuvastatin vs. 216 on
placebo, P ¼ 0.01), the point estimate for CV risk reduction
associated with rosuvastatin (HR 0.63, 95% CI 0.25e1.60)
was consistent with that for the whole study (HR 0.56, 95%
CI 0.46e0.69). Together, these studies suggest that the
short-term risk of developing T2D in patients without T2D
risk factors is negligible, irrespective of the statin dose.
Further studies are required to examine whether statins
cause T2D per se or simply accelerate the progression to
T2D in people with a pre-disposition for the disorder.5.3. Are the diabetogenic effects similar for all statins?Seven statins are currently available for the treatment of
dyslipidaemiaeatorvastatin, simvastatin, rosuvastatin, pit-
avastatin, lovastatin, pravastatin, and fluvastatin. Whereas
some statins have been associated with elevations in glycae-
mic parameters in patients with and without T2D, others have
demonstrated neutral effects [40,42,44,45,80e95]. However,
since many of these studies did not systematically assess T2D
incidence or were underpowered to detect a difference
between statins, results should be treated with caution.
One of the earliest studies to demonstrate a potential
difference between the diabetogenicity of statins wasa post-hoc analysis of data from the Pravastatin or Ator-
vastatin Evaluation and Infection TherapyeThrombolysis
in Myocardial Infarction (PROVE-IT) 22 trial in which
patients without pre-existing T2D (N ¼ 3382) showed
a 0.30% increase from baseline in HbA1c levels with
atorvastatin 80 mg and a 0.12% increase with pravastatin
40 mg (P < 0.0001) [83]. To determine whether individual
statins have differing effects on insulin sensitivity (IS),
a meta-analysis of 16 studies (N ¼ 1146) was carried out in
patients without pre-existing T2D [91]. When pooled as
a class, statins had no significant effect on IS compared
with placebo. However, individual comparisons showed
that, whereas IS was significantly improved with pravas-
tatin (P ¼ 0.03 versus placebo), there was a non-significant
deterioration in IS with atorvastatin and rosuvastatin and
a significant deterioration with simvastatin (P ¼ 0.03).
Major limitations of this analysis include between-study
differences in the method used to measure IS and failure
to consider varying doses or durations of statin treatment.
These results should therefore be considered preliminary
and further large-scale trials would be helpful.
More recently, a meta-analysis of 17 RCTs including
113,394 patients without pre-existing T2D showed that,
among the three low-dose statins assessed, pravastatin
10e20 mg/day was associated with the lowest risk for
incident T2D (OR 0.90 vs placebo; 95% CI 0.71e1.35)
followed by atorvastatin 10 mg (1.04; 0.75e1.46) and then
rosuvastatin 10 mg (1.11; 0.81e1.52) [92] (see Appendix).
Although the 95% CIs were large in these studies and
overlap, the order of risk was replicated when the effects of
moderate- to high-dose statins were compared (lovastatin
20e40 mg < pravastatin 40 mg < atorvastatin
80 mg < simvastatin 40 mg < rosuvastatin 20 mg) and
results remained similar in several other ranking analyses.
A population-based cohort study carried out in 471,250
Canadian subjects without T2D showed that patients taking
atorvastatin, simvastatin or rosuvastatin had an increased
risk of developing T2D compared with those treated with
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[1.04e1.17] and 1.18 [1.10e1.26], respectively (see
Appendix) [44]. This translated into an absolute risk for
incident T2D of 31, 34 and 26 events per 1000 person years
compared with 23 per 1000 person years for pravastatin.
Crude event rates for fluvastatin and lovastatin (21.52 and
21.80 events per 1000 person years, respectively) were
similar to those observed with pravastatin and the order of
diabetogenicity was the same regardless of whether statins
were used for the primary or secondary prevention of CVD.
Although similar results were observed when statins were
grouped by potency, the risk of incident T2D associated
with use of rosuvastatin became non-significant (adjusted
HR 1.01; 0.94e1.09) when dose was taken into account.
Finally, a retrospective cohort study carried out in
239,628 statin-treated patients from Irish primary care
clinics demonstrated a significantly increased risk of inci-
dent T2D with atorvastatin (adjusted HR 1.25; 95% CI
1.21e1.28), simvastatin (1.14; 1.06e1.23) and rosuvastatin
(1.42; 1.33e1.52), but not for pravastatin (1.02; 0.98e1.06)
or fluvastatin (1.04; 0.91e1.18) (see Appendix) [45]. This
study showed statistically significant overall dose and
duration effects for all statins except fluvastatin, which only
demonstrated a duration effect.
Whilst the above two observational studies are of
interest, there remains potential for bias by factors
including allocation bias. Additionally, the baseline risk of
developing T2D is likely to vary between individuals
allocated to different statin regimens, hence the most reli-
able information will likely come from meta-analyses of
data from randomised controlled trials. To date, however,
the only large-scale clinical trial specifically designed to
investigate the effects of a statin on incident T2D is the
Japan Prevention Trial of Diabetes by Pitavastatin in
Patients with Impaired Glucose Tolerance (J-PREDICT)
study [93]. Preliminary results from this prospective rand-
omised, open-label, probe-design study show that lifestyle
modification plus low- to moderate-dose (1e2 mg/day)
pitavastatin was associated with a significant reduction in
the cumulative incidence of T2D (defined either as 2-h
plasma glucose  200 mg/dL or FPG  126 mg/dL
measured at least once) in high-risk patients with IGT
(N ¼ 1269) compared to lifestyle modification alone. A
number of small and/or retrospective studies examining the
effects of pitavastatin on glycaemic control potentially
support these results (see Appendix). However, further
large-scale head-to-head trials are required to investigate
the dose- and duration-effects of pitavastatin and to
compare these effects with those of other high-potency
statins.
Overall, the data published to date should be interpreted
to indicate that the diabetogenicity of statins is a ’class
effect’. However, data are still evolving and there are signals
that some statins have a potentially neutral effect on gly-
caemic control (see Appendix). As always, results from
meta-analyses and prospective studies require confirmationin large-scale head-to-head clinical trials. Further studies are
also required to investigate whether the observed differences
are due to diabetogenicity per se or whether they are simply
due to differences in study population (i.e. age or level of
T2D risk at baseline), the method used to diagnose T2D,
statin dose, and/or the potency and duration of treatment.
6. Mechanistic rationale for the diabetogenic effects of
statins
T2D is a complex disorder characterised by both
pancreatic beta cell dysfunction and insulin resistance of
skeletal muscle, adipose tissue and liver. The precise
reasons for the increased incidence of T2D with statins
have not yet been identified. Possible explanations include
residual confounding factors, such as improved survival
with statin treatment and a greater chance of identifying
incident T2D in statin-treated patients. However, analysis
of electronic medical records from 500 UK general prac-
tices (285,864 men and women aged 50e84 years) showed
that, during 1.2 million person-years of follow up, the risk
of developing T2D (HR 1.45; 95% CI 1.39e1.50) was
unaffected by survival rates [96]. The same observation (i.e.
HR giving near identical values to OR) was evident in three
of the trials with relevant data included in the comparison
of diabetes risk by intensive versus standard dose statins
discussed previously [38]. Another possible explanation is
that, rather than causing T2D per se, statins simply accel-
erate its progression in people with pre-existing risk factors.
Further work is needed to fully investigate this possibility.
Several biological mechanisms have been proposed for
the diabetogenic effects of statins [40,43,97e99]. Under
normal conditions, glucose enters pancreatic beta cells [97],
skeletal muscle cells [100] and adipocytes [101] via insulin-
responsive transmembrane glucose transporters (Glut 2 and
Glut 4). Once inside the cell, glucose is phosphorylated by
glucokinase, generating glucose-6-phosphate, which is
subsequently metabolised to pyruvate. Pyruvate then enters
the mitochondria, where it is metabolised as part of the
tricarboxylic acid cycle to produce ATP. In beta cells, cyto-
solic ATP closes potassium channels, depolarises the
membrane, and activates voltage-gated calcium channels,
causing calcium to enter the cell and stimulate insulin
secretion. In muscle, glucose is used for energy; in adipose
tissue (where uptake is low), glucose is converted to fatty
acids and stored as triglyceride. A number of animal and cell-
based studies have reported statin-associated alterations in
glucose metabolism that could result in decreased insulin
secretion and/or insulin resistance [40,43,97e99]. In some of
these studies, differences between statins have been
observed. Further research into the mechanisms underlying
statin-mediated T2D, possibly focused on mechanisms that
have been linked to muscle dysfunction [102e104], will help
us understand whether the potential differences in dia-
betogenicity between statins discussed in Section 4 (see
Appendix) are real.
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In order to fully understand the best treatment strategy for
people with or at risk of developing statin-mediated T2D,
a number of outstanding questions need to be answered. In
addition to understanding whether there are differences
between statins in diabetogenic potential, studies are required
to determine whether statin-mediated changes in glucose
levels represent true T2D (i.e., is statin-related hyper-
glycaemia reversible after cessation of statin-therapy?), and,
to what extent long-term statin use impairs long-term gly-
caemic control in patients with established T2D.7.1. Is the diabetogenicity of statins consistent across
all patient groups?In general, Asian populations are more responsive to the
LDL-lowering effects of statins than Caucasians, primarily
due to genetic differences in statin metabolism at the level
of drug transporters and hepatic enzymes [105]. However,
very few studies have compared the diabetogenic effects of
statins across different races. Recently, a sub-analysis of
observational data from the Women’s Health Initiative
(WHI) suggested that, compared to statin non-users, statin-
treated post-menopausal women (N ¼ 3922) from Asia and
the Pacific Islands had a non-significant trend towards
a higher risk of developing T2D (HR 1.78; 95% CI
1.32e2.40) than their Caucasian (HR 1.49; 1.38e1.62) and
African American counterparts (HR 1.18; 0.96e1.45)
[106]. These results must be cautiously interpreted given
the observational nature of the data.
Additional work is also required to understand the impact
of age on statin diabetogenicity. Studies have shown that the
risk of developing T2D increases with age, whereas the CV
benefits of LDL-C-lowering are diminished [107,108].
Consequently, statin therapy (in particular high-dose statins)
is substantially underused among older patients [109]. A
meta-regression analysis of data from Sattar et al. [39]
suggested that the association between statin therapy and
the risk of incident T2D may be stronger in older versus
younger participants. In contrast, no relationship was found
with baseline BMI and the percentage change in LDL-C.
These latter findings should be treated with caution,
however, given the exploratory nature of the analyses.7.2. Do statin-mediated changes in glucose levels
potentially attenuate their CVD risk benefits?Like statins, thiazide diuretics are associated with an
increased risk of developing T2D [110]. The increases in
blood glucose levels seen with thiazide diuretics are
reversed when drugs are discontinued, even after many
years of treatment [111]. Long-term studies are required to
investigate the effects of statin-cessation on glycaemic
control. In the meantime, statin-induced T2D should be
considered and treated the same as established T2D.7.3. Understanding the link between dysglycaemia
and CVD riskRecent studies have shown that, although both early- and
late-onset T2D are associated with an increased risk of
major CHD events and mortality, the risk associated with
T2D only appears to be a CHD equivalent after a long
duration (>10 years) of T2D [62]. Moreover, whereas the
risk of CHD events is associated with levels of FPG in the
‘at-risk for T2D’ and T2D range (>5.6 mmol/L; 100 mg/
dL), there appears to be only a modest correlation between
FPG levels in the low-risk range (5.6e7.0 mmol/L;
101e126 mg/dL) [51]. Together, these studies suggest that
the duration of frank hyperglycaemia (i.e. sufficient to be
diagnosed with T2D) contributes significantly to the asso-
ciation between T2D and vascular risk and that it might not
be appropriate to extrapolate the glucose changes seen
during statin therapy to an equivalent increase in CV events
seen in other patients with T2D. Only robust, longer-term
cohort data can address these questions.
8. Recommendations for the use of statins in patients
with, or at risk of developing, T2D
Recommendations for the use of statins in patients at
risk of developing T2D: The decision to prescribe a statin
should always take into account risk vs. benefit. It is clear
that the benefits of statin-use far outweigh the small abso-
lute risk of developing T2D in patients with elevated CV
risk and that, even if a patient develops T2D, the risks
associated with CVD are much greater than the risks
associated with T2D. Indeed, individuals with a higher risk
of developing T2D have an increased risk for CVD and are
therefore likely to gain greater absolute benefit from statin
therapy than those with low T2D risk. Given that the
current guidelines only recommend statins for patients with
high- to very-high CV risk [2,3,8,11], statins should
continue to be allocated based on existing CVD guidelines
without regard to T2D risk. More recent reductions in CVD
risk thresholds for statin treatment will still not be influ-
enced by the diabetes risks, although of course lifestyle
advice to prevent diabetes needs to be strongly reinforced.
Compared to less-intensive statin therapy, more-
intensive therapy is associated with a highly significant
15% further reduction in major vascular events (95% CI
11e18; P < 0.0001) [20]. However, according to a recent
meta-analysis, intensifying therapy is also associated with
a 12% higher incidence of T2D [38]. This suggests that the
number needed to harm per year for intensive- versus
standard-dose therapy is 498 for incident T2D, whereas the
number needed to treat per year is 155 for CV events. In
absolute terms, intensive statin therapy accounts for 3.0
additional cases of T2D and 6.5 fewer first major CVevents
per 1000 patient-years. Again, the benefits for high- versus
standard-dose statins outweigh the absolute risk of devel-
oping T2D in patients with high CV risk. This suggests that
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accordance with international guidelines [2,3,8,11] (Fig. 4).
Before prescribing a statin, physicians should assess
each patient’s CV and T2D risk, as described in Sections 2
and 3 [8]. They should then discuss the possible conse-
quences of statin therapy with their patients and encourage
them to reduce both their CV and T2D risk through inten-
sive lifestyle changes. Overall, available evidence suggests
that the short-term risk of developing statin-mediated T2D
in patients without any risk factors for T2D is low irre-
spective of statin dose and that the risk gradually increases
with increasing numbers of T2D risk factors [35,41,78,79]
(Section 4). In our opinion, all patients with high CV risk
considered for statins should have their risk for T2D
assessed initially using a validated risk score. If their risk
score shows low- to moderate-T2D risk (e.g. FINDRISC
score <15 or equivalent using other T2D risk scores) then
HbA1c and/or FPG levels need not be assessed (Fig. 4). In
contrast, in patients with CVD and/or high CV risk and
high- to very-high T2D risk scores (e.g. FINDRISC
score  15 or equivalent), HbA1c or FPG levels should be
measured pre-statin and re-assessed 3 months after statin
initiation (Fig. 4). In patients with a high T2D risk score
and/or FPG > 100 mg/dL/5.5 mmol/L or HbA1c
6.0e6.4%, appropriate measures should be taken to reduce
the risk of conversion from pre-diabetes to T2D. We
suggest this might include targeting weight loss and
reductions in glycaemia through more intensive lifestyle
changes with or without T2D treatment.8.1. Case study 1: patient with high CV risk and high
T2D riskA white, British, 60-year old man without CVD or T2D
symptoms but with concerns about his general health pre-
sented for a health check. His BMI was 34 kg/m2, his waist
circumference 110 cm, he smoked and rarely exercised.
Untreated blood pressure was 155/90 mmHg on repeatFig. 4. Recommendations for glycaemia testing pre- and post- statin comtesting; fasting bloods revealed TG 2.5 mmol/L (225 mg/
dL), LDL-C 3.3 mmol/L (128 mg/dL) and a non-HDL-C
4.5 mmol/L with HDL-C 1.0 mmol/L (39 mg/dL) and
total cholesterol 5.5 mmol/L (213 mg/dL). The patient’s
father had an MI at the age of 52 years and was recently
diagnosed with T2D. In accordance with the 2013 ESC/
EASD guidelines [8], the patient was assessed for overall
CV risk using SCORE charts and for T2D risk using the
FINDRISC chart. He was found to have a high CV risk (5%
chance of 10-year CV mortality) and a high (1 in 3) risk of
developing T2D within 10 years. HbA1c level was 6.3%.
The physician discussed the consequences of statin therapy
with the patient and advised him to reduce his CV and T2D
risk through intensive lifestyle changes. A moderate-
intensity statin was prescribed to reduce LDL-C to
2.5 mmol/L (100 mg/dL) and the patient was asked to
return to the clinic for follow-up. After 3 months, LDL-C
was below the recommended target and he had lost some
weight through sustainable changes in his diet. However,
his BMI remained 33 kg/m2 and HbA1c was still 6.3%.
Lifestyle advice was reinforced and the patient was re-
assessed for LDL-C and T2D risk every year.8.2. Case study 2: patient with low CV risk and high
T2D riskA 35-year old man living in France with total cholesterol
5.8 mmol/L (232 mg/dL), LDL-C 3.5 mmol/L (135 mg/
dL), TG 3.5 mmol/L (310 mg/dL) and HDL-C 1.10 mmol/L
(43 mg/dL) presented at a clinic with T2D symptoms. Both
parents were diagnosed with T2D relatively early in life.
The patient’s BMI was 31 kg/m2, waist circumference was
103 cm, he had a sedentary lifestyle, poor diet, had never
smoked and his BP was 120/75 mmHg. In accordance with
the 2013 ESC/EASD guidelines [8], the patient was
assessed for overall CV risk using SCORE charts and T2D
risk using FINDRISC charts. His overall 10-year risk of CV
mortality was found to be extremely low (<1%) but hismencement in individuals without known diabetes [3,8,11,33,55].
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uated and found to be 6.0%. The patient was given lifestyle
advice and was asked to return for repeat HbA1c
measurement. HbA1 levels were reduced to 5.8%. As the
patient’s CV risk was low, no statins were prescribed and
the patient was kept under annual review by his General
Practitioner.8.3. Recommendations for the use of statins in
patients who develop T2D during statin treatmentNumerous studies have shown that LDL-C-lowering
using statins significantly reduces CV risk in people with
established T2D and that further reductions in CV risk can
be obtained using more- vs. less-aggressive treatment [21].
Consequently, international treatment guidelines currently
recommend statins as the first-line lipid-lowering pharma-
cotherapy in the majority of people with T2D
[2e4,11,15,54,55]. However, studies have yet to show
whether statin-mediated changes in glucose levels represent
true T2D and whether these changes can be reversed when
statin treatment is stopped (Section 6). Moreover, the impact
of statin-mediated T2D on both micro- and macrovascular
risk is still unknown over the longer term. In general the
benefits of LDL-C reduction on CVD prevention outweigh
the potential CVD risk from elevated blood glucose levels.
Patients that develop T2D during statin therapy should
therefore continue with therapy according to national
guidelines and be encouraged to reduce their risk of devel-
oping T2D-related complications (including CVD) through
lifestyle changes.
9. Conclusions
Statins are the recommended first-line lipid-lowering
drugs for the majority of patients with any level of CV risk.
Although they are generally considered to be safe and well-
tolerated, recent studies have demonstrated a dose-
dependent increase in T2D with statins (Figs. 2 and 3). A
number of plausible mechanisms have been suggested to
support this effect (Section 5), but definitive proof for
responsible mechanisms is lacking. Although our under-
standing of the diabetogenic effects of statins is increasing,
more evidence is required to fully understand the impact of
ethnicity, gender and age. Moreover, it is not yet known
whether other drugs that increase glucose levels, such as
beta-blockers and thiazide diuretics, increase the diabeto-
genic effect of statins or whether drugs that improve gly-
caemic control can attenuate potential statin-induced
glycaemic changes e.g on microvascular disease. Until
long-term data become available, patients with statin-
induced elevations in blood glucose above the T2D
threshold should be treated in the same way as those
developing T2D de novo.
It is clear that the benefits of statin-use for the reduc-
tion of CV risk far outweigh the risk of developing T2D inthe majority of patients. In all cases, patients should be
assessed for their risk of developing T2D both before and
during statin therapy. Physicians should then discuss the
possible consequences of statin treatment with their
patients and strongly encourage them to reduce both their
CV and T2D risk through lifestyle changes. There is
currently no evidence to suggest that a patient who
develops T2D during statin treatment should discontinue
treatment. Broadly speaking, patients should continue
with their statin therapy in accordance with national
guidelines, and the statin link to T2D should be used to
further incentivise patients to adhere with lifestyle
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Studies comparing the diabetogenic effects of statins.
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Main observations
113, 394) >1 year Increased risk of T2D vs placebo (OR 1.11; 95%
CI 0.81e1.52)
hort study 14 years Increased risk of T2D vs pravastatin (adjusted
HR 1.18; 1.10e1.26)
t study 6 years Increased risk of T2D vs no statin (adjusted HR
1.42; 1.33e1.52)
hort study 14 years Increased risk of T2D vs pravastatin (adjusted
HR 1.10; 1.04e1.17)
t study 6 years Increased risk of T2D vs no statin (adjusted HR
1.14; 1.06e1.23)
113, 394) >1 year Slightly increased risk of T2D vs placebo (OR
1.04; 95% CI 0.75e1.46)
hort study 14 years Increased risk of T2D vs pravastatin (adjusted
HR 1.22; 1.15e1.29)
t study 6 years Increased risk of T2D vs no statin (adjusted HR
1.25; 1.21e1.28)
113, 394) >1 year Reduced risk of T2D versus placebo (OR 0.90;
95% CI 0.71e1.35)
t study 6 years No change in T2D risk vs no statin (adjusted HR
1.02; 0.98e1.06)
ised, open-
(N ¼ 1269)
Reduced risk of T2D vs lifestyle changes
analysis
double-blind,
comparing
4) with
4)
12 weeks No clinically-relevant glycaemic changes vs
baseline for pitavastatin or pravastatin
study
tin 4 mg
astatin 40 mg
56 weeks Pitavastatin: No change in FPG vs baseline at 12
or 56 weeks; Simvastatin: No change in FPG
after 12 weeks; significant increase in FPG after
56 weeks
08) of the
rketing
study
104 weeks Significant (P < 0.001) 0.28% decrease in
HbA1c levels vs no treatment
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